Send the following on WhatsApp
Continue to ChatI liked this article on M3 India: Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): A multicenter, open-label, phase 2 trial . Have a read: https://www.m3india.in/contents/journal/niraparib-in-patients-with-metastatic-castration?utm_campaign=unset&utm_medium=share&utm_source=ref_wa